PathAI Expands PathExplore Reach to 14 Cancer Types, Fueling Precision Oncology

From HIT Consultant regarding PathAI:

What You Should Know:

• PathAI, a pioneer in AI-powered pathology, announced a significant expansion of its PathExplore platform, adding six new oncology indications to its arsenal.
• The expansion doubles the platform’s reach, now covering 14 different cancer types, and further solidifies PathExplore as the leading tool for characterizing the tumor microenvironment (TME) from H&E-stained whole-slide images (WSIs).

Bridging the Gap in Cancer Research

Despite advances in cancer treatment, many patients remain unresponsive to available therapies or lack access to potentially life-saving options due to the absence of actionable biomarkers. The TME, a complex ecosystem of cells and tissues surrounding the tumor, holds immense potential for unlocking new therapeutic targets. However, traditional analysis methods struggle to capture the full resolution and spatial intricacies of this intricate landscape.

PathExplore Unleashes the Power of AI

PathExplore addresses this challenge head-on by leveraging AI to analyze H&E-stained WSIs. Its standardized and scalable panel of human interpretable features (HIFs) provides researchers with a comprehensive picture of the TME, including cell types, tissue structures, and their spatial relationships. This detailed information empowers scientists to identify potential biomarkers, predict treatment responses, and develop more targeted therapies.

Expanding the Battleground against Cancer

The initial launch of PathExplore in April 2023 covered eight major cancer types: non-small cell lung, breast, colorectal, skin, gastric, prostate, kidney, and pancreatic. Today’s expansion adds six more crucial players to the fight: ovarian, bladder, liver, small cell lung, lymphoma, and head and neck cancers. This broader reach allows researchers to explore the TME across a wider spectrum of the disease, accelerating the discovery of new insights and personalized treatment options.

A Proven Partner in Precision Oncology

Since its launch, PathExplore has established itself as a trusted ally in the fight against cancer. With over 50 partnerships across pharma, biotech, academia, and laboratories, PathAI has analyzed over 150,000 WSIs and contributed to more than 50 publications and presentations. This impressive track record underscores the platform’s effectiveness and its potential to revolutionize cancer research and treatment.

The Future of Precision Oncology is Now

By unlocking the secrets of the TME and empowering researchers with actionable insights, this powerful platform is paving the way for a future where every patient receives the most effective treatment possible.

“Pathology is the only data modality to define and quantify morphological changes resulting from treatment or disease progression,” said Andy Beck, M.D., Ph.D., chief executive officer and co-founder of PathAI. “PathExplore enables researchers and drug developers to effortlessly investigate standard characteristics of the TME, such as the abundance of tumor-infiltrating lymphocytes, as well as spatial characteristics that were previously impossible to measure such as the ratio of lymphocytes to fibroblasts near the epithelial-stromal interface.”

SOURCE: HIT Consultant